|Bid||294.01 x 100|
|Ask||302.00 x 500|
|Day's Range||290.29 - 296.91|
|52 Week Range||244.28 - 329.83|
|PE Ratio (TTM)||18.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.
Biogen Inc. gained more than $1 billion in market value Wednesday morning after Goldman Sachs, one of the world’s largest investment banks, added the drug developer to its closely-watched Equity Conviction List. Goldman Sachs analysts Terence Flynn and Cameron Bradshaw issued a research note this morning announcing that Cambridge-based Biogen (BIIB) was added to the list, which is essentially a strong recommendation to general investors to buy stock in a certain company. In their research note, Flynn and Bradshaw pointed specifically to Biogen’s experimental drug to treat Alzheimer’s disease, called aducanumab, as a prime reason for the company’s inclusion on the list.
Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.